Cyprotex PLC Launch of New Toxicity Guide
July 11 2013 - 02:00AM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
11 July 2013
Cyprotex PLC
("CRX" or "the Company" or "the Group")
Cyprotex launches new 'Mechanisms of Drug-Induced Toxicity'
guide
11 July, 2013 - Cyprotex PLC, a specialist ADME-Tox Contract
Research Organisation, today announces the launch of its third
educational guide. Following the success of 'Everything you needed
to know about ADME but were too afraid to ask' and 'DDI regulatory
guidance - an easy to follow guide', Cyprotex introduces the latest
addition entitled 'Mechanisms of drug-induced toxicity'.
The new handbook provides a valuable resource for scientists in
a range of disciplines who wish to gain an overview of the key
mechanisms involved in drug-induced toxicity. It also includes
details on the latest in vitro methodologies used for screening for
drug-induced toxicity.
Research and knowledge in the field of in vitro toxicology is
expanding rapidly. Cyprotex is at the forefront of this, developing
novel cellular models and techniques for accurately predicting
drug-induced toxicity, often working in conjunction with other
groups. Cyprotex believes that the sharing of knowledge in this
specialised field is important to further progress understanding
and reduce late stage toxicology-related attrition.
Commenting on the launch of the new handbook, Dr. Anthony
Baxter, Chief Executive Officer of Cyprotex, said: "There is a
concerted effect within the pharmaceutical industry to reduce late
stage attrition related to toxicity and move towards earlier in
vitro screens which are more predictive of clinical outcome. Our
ability to develop accurate in vitro models combined with in silico
approaches has proved fruitful in this respect and Cyprotex are
committed to continuing research in this important field. Our
educational guides are well known and respected in the industry and
I am delighted to launch our latest guide on Mechanisms of
Drug-Induced Toxicity."
To request a copy of our 'Mechanisms of Drug-Induced Toxicity'
handbook, visit: http://www.cyprotex.com/toxguide/
For further information:
Cyprotex PLC Tel: +44 (0) 1625 505
100
Dr Anthony Baxter, Chief Executive Officer ir@cyprotex.com
John Dootson, Chief Financial Officer www.cyprotex.com
Mark Warburton, Chief Operating Officer and
Legal Counsel
N+1 Singer (Nomad and broker to Cyprotex) Tel: +44 (0)20 7496 3000
Shaun Dobson shaun.dobson@n1singer.com
Jenny Wyllie jenny.wyllie@n1singer.com
www.n1singer.com
FTI Consulting Tel: +44 (0) 20 7831
3113
Simon Conway cyprotex@fticonsulting.com
Mo Noonan www.fticonsulting.com
Notes to Editors
About Cyprotex PLC
Cyprotex is based in Macclesfield, near Manchester in the UK,
and Watertown, MA in the US and is listed on the AIM market of the
London Stock Exchange (CRX). The company was established in 1999
and works with more than 700 partners. Cyprotex acquired Apredica
and the assets of Cellumen Inc. in August 2010 and the combined
business provides support for a wide range of experimental and
computational ADME-Tox and PK services, extending from early drug
discovery through to IND submission. The company's core
capabilities include high quality in vitro ADME screening services,
mechanistic toxicology and high content toxicology screening
services including CellCiphr(R) Premier and eCiphrCardio, and
predictive modelling using PBPK and QSAR techniques including
Cloe(R) PK for in vivo PK prediction. For more information, see
www.cyprotex.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRARMMFTMBABBTJ
Cyprotex (LSE:CRX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2023 to Mar 2024